Tiselizumab’s Mechanism of Action in Patients with Hepatocellular Carcinoma
Ghassan K. Abou-Alfa, MD, a medical oncologist at Memorial Sloan Kettering Cancer Center, discusses tiselizumab’s mechanism of action in patients with hepatocellular carcinoma.
Ghassan K. Abou-Alfa, MD, a medical oncologist at Memorial Sloan Kettering Cancer Center, discusses tiselizumab’s mechanism of action in patients with hepatocellular carcinoma (HCC).
Tiselizumab is an investigational anti-PD1 monoclonal antibody, according to Abou-Alfa. It has a high affinity for PD-1 due to the fact it’s designed to minimize the bindings of FC gamma receptors to microphages. This process limits antibody-dependent phagocytosis.
This allows T cells to come into full play, says Abou-Alfa. However, due to the FC gamma receptors, this may be a more laborious process. With the extra assets provided by tiselizumab, some of the challenges may be alleviated, according to Abou-Alfa.
Hope Beyond Surgery: Optimizing Care for Cholangiocarcinoma
February 15th 2024In an interview for Cholangiocarcinoma Awareness Day, Domenech Asbun, MD, discussed how the management of cholangiocarcinoma continues to evolve and addressed unmet needs in early detection and systemic therapy.
Read More
Durvalumab/Bevacizumab/TACE Significantly Extends Survival in HCC
February 6th 2024In an interview with Targeted Oncology, Bruno Sangro, MD, PhD, discussed the potential durvalumab, bevacizumab, and TACE has to set a new standard-of-care among patients with unresectable hepatocellular carcinoma.
Read More
